Manipal Health Enterprises IPO Listing: Shares List at a premium of 10.51% on NSE & at 11.02% on BSE

Key takeaways:

• Manipal Health Enterprises listed at ₹652 on the NSE and at ₹655 on the BSE, delivering a healthy premium of 10.51% and 11.02% respectively.
• The mega ₹9,275.22 crore public issue was oversubscribed by 4.92 times with significant participation from Qualified Institutional Buyers (QIBs).
• The company has a pan-India healthcare ecosystem comprising 49 multi-speciality hospitals and more than 13,000 licensed beds.
• Manipal Health Enterprises reported strong top-line performance, with total income of ₹10,520.52 crore and Profit After Tax (PAT) of ₹916.52 crore in FY26.

Manipal Health Enterprises, India's largest private hospital network by licensed bed capacity, made its highly anticipated debut on the Indian capital markets today. The company went public by listing its equity shares on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE).

The initial public offering (IPO) was a book-built issue of ₹9,275.22 crores, comprising an ₹8,000 crore fresh issue and an offer for sale (OFS) of ₹1,275.22 crore. The IPO listed at a healthy premium of 10.51% on the NSE today at ₹652 per share and at a premium of 11.02% on the BSE at ₹655 per share against the upper price band of ₹590 per share.

Here, we will explore the Manipal Health Enterprises IPO listing performance and its fundamentals.

Manipal Health Enterprises IPO - Listing performance

Manipal Health Enterprises' shares were officially listed on the Indian stock exchanges today, August 5, 2026. The shares are listed at ₹652 on the NSE (a 10.51% premium) and ₹655 on the BSE (a 11.02% premium). This positive listing was not in sync with its Grey Market Premium (GMP) signals leading up to the debut, as it had a better-than-anticipated listing.

The GMP had gradually cooled down from a high of ₹35 to around ₹9 to ₹3 in the last few days before listing, which indicated a mild listing gain of around 1%. Retail investors were cautious as the company was carrying a huge debt load and had premium pricing. On the other hand, the institutional demand helped to ensure a positive open.

About Manipal Health Enterprises 

Manipal Health Enterprises was incorporated in 2010 and is a leading pure-play healthcare services provider in India. With the support of the Manipal Group, it specialises in tertiary and quaternary care in various specialities such as cardiac sciences, oncology, neurosciences and orthopaedics.

The company currently has a wide network of 49 hospitals and 13,037 licensed beds in 14 states and union territories as of March 2026. It has strategically expanded its footprint with key acquisitions like AMRI Hospitals, Medica Synergie and recently Sahyadri Hospitals.

The company has shown strong revenue growth. Its total income jumped by around 26% to ₹10,520.52 crore in FY26. But its aggressive expansion and high finance costs on borrowings resulted in a PAT (Profit After Tax) decline of 15% to ₹916.52 crore for the year.

Manipal Health Enterprises IPO journey

The IPO of Manipal Health Enterprises was opened on July 29, 2026 and closed on July 31, 2026. The company offered shares in the range of ₹560 to ₹590 per equity share with a minimum retail lot size of 25 shares which required an investment of ₹14,750.

The primary objective of this IPO was to reduce debt; Manipal intends to use a major part of the proceeds from the IPO to prepay the borrowings of its subsidiary, Manipal Hospitals Pvt Ltd, and to buy a minority stake in Sahyadri Hospitals Pvt Ltd. 

The overall subscription for the IPO closed at 4.92 times. The retail and Non-Institutional Investor (NII) categories didn’t show massive interest. They only subscribed 0.98 times and 1.06 times, respectively, but the Qualified Institutional Buyers (QIBs) led the demand on the last day, oversubscribing their quota by 8.54 times. This IPO issue also had an employee quota, which was 2.32 times subscribed.

Wrap up 

The positive listing of Manipal Health Enterprises underscores the investor interest in India's fast-growing, but capital-intensive, hospital industry. The listing premium of ~11% indicates a stellar debut, with the company's fundamentals making it an interesting investment for long-term investors.

As the company embarks on its journey as a publicly listed giant, its ability to reduce debt, integrate its recent acquisitions, and sustain its EBITDA margins will be the key determinants of long-term wealth creation.